|
業務類別
|
Biotechnology |
|
業務概覽
|
LB Pharmaceuticals Inc is a late-stage biopharmaceutical company developing novel therapies for the treatment of a wide range of neuropsychiatric disorders including schizophrenia, bipolar depression, adjunctive treatment of depressive disorder and other diseases. It is building a pipeline that leverages the broad therapeutic potential of its product candidate, LB-102, which it believes has the potential to be the first benzamide antipsychotic drug approved for neuropsychiatric disorders in the United States. LB-102 is currently in late-stage clinical development for schizophrenia and bipolar depression. The company operates as a single reportable segment in the development of novel therapies for the treatmentof neuropsychiatric diseases, including schizophrenia. |
| 公司地址
| One Pennsylvania Plaza, Suite 1025, New York, NY, USA, 10119 |
| 電話號碼
| +1 212 605-0300 |
| 傳真號碼
| -- |
| 公司網頁
| https://www.lbpharma.us |
| 員工數量
| 27 |
| Dr. Richard Anthony Silva, PhD |
Senior Vice President, Technical Operations |
-- |
23/04/2026 |
| Ms. Heather Turner |
Chief Executive Officer and Director |
美元 568.75K |
10/03/2026 |
| Mr. Marc Panoff |
Principal Financial Officer, Principal Accounting Officer and Senior Vice President, Finance |
-- |
23/04/2026 |
| Mr. Gad Soffer |
Chief Operating and Business Officer |
美元 402.29K |
23/04/2026 |
| Dr. Anna Eramo, M.D. |
Chief Medical Officer |
美元 414.06K |
23/04/2026 |
| Ms. Kaya Kamlesh Pai Panandiker |
Chief Commercial Officer |
-- |
23/04/2026 |
|
|
| Ms. Rekha Hemrajani, M.B.A. |
Independent Director |
23/04/2026 |
| Dr. Robert R. Ruffolo, D.Sc.,Jr,PhD |
Independent Director |
23/04/2026 |
| Dr. Zachary Prensky, M.D. |
Director |
16/03/2026 |
| Mr. Scott Garland |
Chairman of the Board |
23/04/2026 |
| Dr. Ran Nussbaum, M.D. |
Independent Director |
23/04/2026 |
| Ms. Heather Turner |
Chief Executive Officer and Director |
10/03/2026 |
| Dr. Robert A. Lenz, M.D.,PhD |
Director |
10/03/2026 |
| Dr. Rebecca Luse, M.D. |
Independent Director |
23/04/2026 |
| Mr. William P. Kane, Jr |
Independent Director |
23/04/2026 |
|
|
|
|
